Angiogenesis and tumor growth
|
|
- Dora Norris
- 6 years ago
- Views:
Transcription
1 Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133:
2 Angiogenesis is a tightly regulated balance The angiogenic switch On Off = Pro-angiogenic factors (e.g. VEGF, PlGF, bfgf, IL-8) = Anti-angiogenic factors (e.g. thrombospondin-1, angiostatin, IFN-a/b) Hanahan, Folkman. Cell 1996 Targets of Antiangiogenic Therapy VEGF Antibodies VEGF Receptor TKI Vascular Damaging Agents (VDA) Scappaticci, F. A. J Clin Oncol; 20:
3 Antiangiogenic Treatment of NSCLC Front-line treatment VEGF-Antibodies Bevacizumab VEGF-TKI Sorafenib Cetiranib Motesanib Other pathways Thalidomide Vascular Disrupting Agents ASA404 Antiangiogenic Treatment of NSCLC Front-line treatment VEGF-Antibodies Bevacizumab VEGF-TKI Sorafenib Cetiranib Motesanib Other pathways Thalidomide Vascular Disrupting Agents ASA404 3
4 E4599 trial design 1 Bevacizumab in NSCLC Previously untreated stage IIIB/IV non-squamous NSCLC (n=878) CP x 6 (n=444) Bev (15mg/kg) every 3 weeks + CP x 6 (n=434) Bev PD* PD AVAiL trial design 2 Placebo + CG x 6 (n=347) PD* Previously untreated, stage IIIB, IV or recurrent nonsquamous NSCLC (n=1,043) *No cross over permitted CP=carboplatin + paclitaxel CG=cisplatin + gemcitabine PD=progression of disease Bev (15mg/kg) every 3 weeks + CG x 6 (n=351) Bev (7.5mg/kg) every 3 weeks + CG x 6 (n=345) Bev Bev PD PD 1. Sandler, et al. N Engl J Med 2006;355: Reck, et al. J Clin Oncol 2009;27: Bevacizumab in Nonsquamous NSCLC Key Results ECOG 4599 AVAIL PCB PC CGB (7.5) CGB (15) CG RR 35% 15% 34.1% 30.4% 20.1% p-value <0.001 < (7.5) (15) PFS (m) HR / p-value 0.66 (<0.001) 0.75 (0.003) / (0.03) / 15 OS (m) HR / p-value 0.79 (0.003) 0.93 (ns) / (ns) / 15 Sandler, et al. N Engl J Med 2006;355: Reck, et al. J Clin Oncol 2009;27: Manegold, et al. ESMO
5 SAiL: Safety of Avastin in Lung First-line, advanced non-squamous NSCLC (n=2,172) Bevacizumab (7.5mg/kg or 15mg/kg) every 3 weeks + standard of care chemotherapy (up to 6 cycles) Bevacizumab to progression PD Primary endpoint: safety of Bevacizumab when combined with chemotherapy Secondary endpoints: efficacy of Bevacizumab (OS, TTP); safety of Bevacizumab in patients who develop CNS metastases CNS = central nervous system SAIL - Safety Patients (%) Grade 3 AEs of special interest in E4599, AVAiL and SAiL 4,4 5,0 4,0 3,6 Bleeding (all types) *Includes haemoptysis AE = adverse event E4599 Bev 15mg/kg + CP AVAiL Bev 15mg/kg + CG AVAiL Bev 7.5mg/kg + CG SAiL Bev 7.5 or 15mg/kg + chemotherapy 1,9 0,9 0,9 0,7 Pulmonary haemorrhage* 7,0 9,0 Median TTP: 7.8 months Median OS: 14.6 months 7,0 5,7 Hypertension 3,0 3,0 2,0 Proteinuria 3,1 Sandler, et al. NEJM 2006 Hirsh, et al. ASCO 2009 Dansin, et al. ECCO-ESMO
6 Bevacizumab Predictive Marker? Selection driven by safety factors (histology, cardiovascular comorbidity, bleeding risk) No predictive marker for efficacy Conclusion Biomarker Avail-Trial: Biomarker involved in angiogenic pathways may play a prognostic role in patients with advanced NSCLC. The role of angiogenic biomarker will be further evaluated (Leighl N et al, ESMO-ECCO 2009) ABIGAIL (BO21015): phase II biomarker trial Previously untreated stage IIIB/IV non-squamous NSCLC (n=300) Bevacizumab 7.5mg/kg + carboplatin/gemcitabine or carboplatin/paclitaxel Bevacizumab 15mg/kg + carboplatin/gemcitabine or carboplatin/paclitaxel Bevacizumab every 3 weeks until progression Bevacizumab every 3 weeks until progression PD PD Primary endpoint: correlation of biomarkers with RR Primary markers: VEGF-A, svegf receptor 1, svegf receptor 2, PlGF, E- selectin Other markers: ICAM, VCAM, bfgf, oestrogen and related receptors, tissue factors 6
7 Efficacy for patients with HTN versus those without Survival Median OS (lower upper limit), months Patients without HTN event N=1, ( ) Patients with HTN event N= ( ) Patients with event (%) Censored patients (%) Progression Median TTP (lower upper limit), months 7.2 ( ) 8.7 ( ) Progressive disease (%) Censored patients (%) Thatcher N et al, WCLC 2009 Choice of chemotherapy? Shaked Y et al, Cancer Cell
8 Antiangiogenic Treatment of NSCLC Front-line treatment VEGF-Antibodies Bevacizumab VEGF-TKI Sorafenib Cetiranib Motesanib Other pathways Thalidomide Vascular Disrupting Agents ASA404 VEGFR-TKI Drug VEGFR 1-3 PDGFR RET C-KIT FLT-3 EGFR RAF Vandetanib ü - ü - - ü - Cediranib ü ü - ü Motesanib ü ü - ü Sunitinib ü ü - ü ü - - Sorafenib ü ü ü ü ü - ü BIBF 1120 ü ü Axitinib ü ü - ü Wedge SR, Clin Cancer Res 2002; Laurie SA, J Clin Oncol 2008; Rosen L, J Clin Oncol 2005; Chow LQ, J Clin Oncol 2005; Wilhelm SM, Cancer Res 2004; Hilberg F, Cancer Res 2008; Schiller J, J Clin Oncol
9 Study Design ESCAPE Chemotherapy phase Maintenance phase Stratification: Geographic region ECOG PS 0 vs 1 Squamous vs non-squamous cell Stage IIIb (with effusion) vs Stage IV n=900 R A N D O M I Z E Carboplatin AUC 6 d1 + Paclitaxel 200 mg/m 2 d1 + Sorafenib 400 mg bid d2-19, q3w (CPS) Carboplatin AUC 6 d1 + Paclitaxel 200 mg/m 2 d1 + Placebo d2-19, q3w (CPP) Sorafenib 400 mg bid Placebo Primary endpoint: Overall survival (Improvement of 30%) Secondary endpoints: Response rate, duration of response, progression free survival, PRO, biomarkers Scagliotti G, J Clin Oncol 2010 (in press) Escape Key results Sorafenib + CP CP Alone P-value Patients Histology Squamous cell 109 (23%) 114 (25%) Response rate 27% 24% ns Median OS (m.) HR 1.15 Median PFS (m.) HR 0.99 Drug related AE 390 (84%) 314 (68%) <0.001 Drug related SAE 78 (17%) 39 (9%) <0.001 Scagliotti G, J Clin Oncol 2010 (in press) 9
10 Overall Survival by Histology Survival Probability HR = % CI: 1.19, 2.74 Squamous Cell CPS Median: 8.9 months 95% CI: 6.1, 13.9 CPP Median: 13.6 months 95% CI: 9.6, Survival Probability Non-Squamous Cell HR = % CI: 0.78, 1.24 CPS Median: 11.5 months 95% CI: 9.7, 14.8 CPP Median: 10.3 months 95% CI: 9.3, Months Months Patients at Risk Patients at Risk CPS CPS CPP CPP Scagliotti G, J Clin Oncol 2010 (in press) Nexus Trial - Amendments Cisplatin/Gemcitabine +/- Sorafenib in patients with stage IIIb/IV NSCLC 10/07 Introduction of OS as Co-Primary Endpoint Patient number: pat DMC: Interim Safety Analysis Recommendation of Exclusion of Squamous Cell Cancer patient due to higher toxicity 04/08 Exclusion of Squamous Cell Cancer patients 07/08 OS only primary endpoint, PFS secondary endpoint, Introduction of two futility interim analyses 02/ randomised patients 10
11 Cediranib CP + Cediranib (45 / 30 mg) CP P-value Patients Response 38% 16% P<0.001 PFS OS (m) HR 0.77, p = 0.13 HR 0.78 P = 0.11 Currently randomized trials using a dose of 20 mg Cediranib on the way Goss GD et al, J Clin Oncol 2010 Motesanib (AMG 706) Randomized, Placebo-controlled, Double-Blind Trial of AMG Paclitaxel/Carboplatin v Placebo + Paclitaxel/Carboplatin 11/ patients enrolled (33% Squamous Cell Histology) stop of recruitment due to safety reasons (squamous cell histology) 03/2009 Amendment Exclusion of patients with Squamous Cell Histology, reopening of recruitment 11
12 Thalidomide 722 patients No interim futility analysis No translational research Lee SM et al, J Clin Oncol 2009 Antiangiogenic Treatment of NSCLC Front-line treatment VEGF-Antibodies Bevacizumab VEGF-TKI Sorafenib Cetiranib Motesanib Other pathways Thalidomide Vascular Disrupting Agents ASA404 12
13 Tumor-VDAs vs Antiangiogenic Agents Disrupt established blood vessels Cause vessel occlusion and inhibition of blood flow Tumor necrosis, major effect on central part of tumor Interfere with new blood vessels Inhibit endothelial proliferation and migration Major effect on peripheral part of tumor Tozer, et al. Nat Rev Cancer 2005;5: Patterson and Rustin. Clin Oncol (R Coll Radiol) 2007;19: Baguley. Lancet Oncol 2003;4: ASA404 + Chemotherapy Surviving ASA P/C P/C 0.3 Treatment ASA P/C P/C 0.2 Median (months) HR (95% CI): 0.73 (0.39, 1.38) Reduction in risk of death: 27% Time (months) ASA P/C P/C Response n = 32 n = 27 PR 10 (31.3%) 6 (22.2%) SD 21 (65.6%) 19 (70.4%) PD 1 (3.1%) 2 (7.4%) 15 McKeage, et al. Br J Cancer 2008;99(12):
14 ASA404: Attract 1 - Study Design Stage IIIB/IV NSCLC All histologies First-line CT naïve PS 0 or 1 Stratification: gender squamous vs non-squamous 08/09 Recruitment finished (1200 pat.) 47% from Europe Results expected 2011 N=1200 Randomization 1:1 Paclitaxel + carboplatin + ASA404 Primary endpoint: overall survival Paclitaxel + carboplatin + placebo Paclitaxel 200 mg/m 2, carboplatin AUC 6, and ASA mg/m 2 or placebo Day 1, q3w, up to six cycles Study drug maintenance treatment (after completion of six cycles of study drug + P/C up to progression) Conclusion Improved efficacy by combination of bevacizumab and chemotherapy in non-squamous cell NSCLC Difficult research for predictive markers Role of VEGFR-TKI in front-line treatment of NSCLC under investigation Squamous cell histology associated with higher risk for toxicity Phase III data for ASA404 pending 14
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPF , HKI 272 XL647, BIBW
Targeted Therapy for Lung Cancer? Emerging Novel targets for NSCLC 11 th UCSF/UCD Thoracic Oncology Conference 11/21/29 Sarita Dubey, M.D., Medical Oncology University of California, San Francisco Cytotoxic
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationAngiogenesi nel NSCLC: stato dell arte
Angiogenesi nel NSCLC: stato dell arte Andrea Camerini Oncologia Medica - Ospedale Versilia Investigator Meeting Study GOIRC Overview Neoangiogenesis in NSCLC (among others) Lots of targets lots of drugs
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationTreatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives
Treatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives Prof. Christian Manegold Medical Faculty Mannheim University of Heidelberg Disclosures Consultancy: Hoffmann-La Roche, Pfizer,
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAntiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño
Antiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño Formigal, 24 de junio de 2016 Antiangiogénesis Sigue siendo una alternativa? Angiogenesis: A hallmark of cancer leading to malignant
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationTargeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC)
46 The Open Lung Cancer Journal, 2010, 3, 46-56 Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC) Athanasios Kotsakis 1 and Taofeek K. Owonikoko *,2 Open Access 1 Division of Hematology-Oncology,
More informationBevacizumab treatment for advanced non small cell lung cancer: A case report
ONCOLOGY LETTERS 6: 1779-1783, 2013 Bevacizumab treatment for advanced non small cell lung cancer: A case report YUN FAN *, ZHIYU HUANG and WEIMIN MAO * Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More informationTargeting Angiogenesis in Advanced Non Small Cell Lung Cancer
Original Article CE 1235 Targeting Angiogenesis in Advanced Non Small Cell Lung Cancer Philip E. Lammers, MD, MSCI, and Leora Horn, MD, MSc Abstract Lung cancer is the leading cause of cancer-related mortality
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationMechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationSURGICAL GRAND ROUNDS
SURGICAL GRAND ROUNDS David H. Harpole, Jr., M.D. New Options for Achieving Individualized Approaches to Non-small Cell Lung Cancer Management Dr. Harpole has financial relationships with the following
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Nonsmall Cell Lung Cancer Christelle Clément-Duchêne, MD,* Yelena Krupitskaya,* Kristen
More informationLung cancer is the leading cause of cancer-related death in the
ORIGINAL ARTICLE Bevacizumab Maintenance in Patients with Advanced Non Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory
More informationBackground. TAP, Paclitaxel + Doxorubicin + Cisplatin
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationAvastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch)
NAME OF THE MEDICINE Avastin bevacizumab (rch) CAS 216974-75-3 Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, consisting of 214 amino acid residues and two 453 residue
More informationSection Heading Lung Section Cancer sub
Section Heading Lung Section Cancer sub Sorafenib in Non-Small Cell Lung Cancer Results of Clinical Trials Wouter W Mellema, MD, 1 Egbert F Smit, MD, PhD 1 and Anne-Marie C Dingemans, MD, Phd 2 1. Department
More informationWhere Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More information